— Why it moved
Why OTLK Stock Doubled Then Faded Today — May 26, 2026
Outlook won its FDA appeal on LYTENAVA — a genuine catalyst — but the entire double printed before 7:45 AM and it faded from there.
What moved OTLK stock
Outlook Therapeutics is a biotech developing ONS-5010/LYTENAVA, a bevacizumab formulation for wet AMD. The FDA granted its appeal in the formal dispute — concluding substantial evidence of effectiveness exists and no new trials are needed — overturning the December CRL and clearing a BLA resubmission for June. A real catalyst for once.
The mechanics
An 83M-share float biotech trading at $0.31 with roughly 11% of the float short. Binary regulatory news on that setup means a violent premarket gap, and 346 million shares changed hands chasing it.
OTLK by the numbers
The alert window
The premarket top, $0.725, printed at 7:42 AM. Stock Pulse flagged it twelve minutes later, at 7:54 AM and $0.6391 — and the post-alert high was $0.6599 at 7:56. Two minutes, 3.3%. Real news, wrong entry: the entire double happened before the alert, and a real-time reader got the leftovers.
How OTLK's move ended
It slid the rest of the day to a $0.3996 close — down 37.5% from the alert, though still up 29% on the day. A resubmission is not an approval: this drug has already eaten two CRLs, and the company will likely need cash before a decision.
The tell: a binary regulatory win on a heavily shorted float prices itself in one violent premarket move — an alert that lands after the top is an entry into the fade, not the trade.